Literature DB >> 7949206

The role of aromatase in breast tumors.

M J Reed1.   

Abstract

Aromatization of androstenedione to estrone in peripheral tissues is the major source of estrogen in postmenopausal women. The aromatase enzyme complex, which mediates the conversion of androstenedione to estrone, is present in several tissues, including adipose tissue and normal and malignant breast tissues. Aromatase activity is detectable in 50-60% of breast tumors, but the contribution that tumor aromatase makes to estrogen concentration in tumors and whether the estrogen formed is biologically important remains a controversial matter. Since concentrations of androstenedione are higher in tumors than in blood, and tumor aromatase activity in vivo may be enhanced by growth factors and by cytokines, the contribution of tumor aromatase to tumor estrogen levels may be higher than suggested by the original calculations. Measurements of tumor aromatase, tumor estrone concentrations, and DNA polymerase alpha activity (a marker of cellular proliferation), in samples obtained before and after treatment with the aromatase inhibitor 4-hydroxyandrostenedione, lend some support to a biological role for estrone formed locally.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949206     DOI: 10.1007/bf00682737

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  45 in total

1.  The effect of glucocorticoids on the in vivo conversion of androstenedione to oestrone.

Authors:  M J Reed; P A Beranek; S Franks; V H James
Journal:  Horm Metab Res       Date:  1986-09       Impact factor: 2.936

2.  Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.

Authors:  R J Santen; S Santner; B Davis; J Veldhuis; E Samojlik; E Ruby
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

3.  Endogenous oestradiol-17beta concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content.

Authors:  M Edery; J Goussard; L Dehennin; R Scholler; J Reiffsteck; M A Drosdowsky
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

4.  The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer.

Authors:  M J Reed; J D Hutton; P M Baxendale; V H James; H S Jacobs; R P Fisher
Journal:  J Steroid Biochem       Date:  1979-07       Impact factor: 4.292

5.  Estrone and estradiol content in human breast tumors: relationship to estradiol receptors.

Authors:  J Fishman; J S Nisselbaum; C J Menendez-Botet; M K Schwartz
Journal:  J Steroid Biochem       Date:  1977-08       Impact factor: 4.292

6.  Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture.

Authors:  S J Santner; S Chen; D Zhou; Z Korsunsky; J Martel; R J Santen
Journal:  J Steroid Biochem Mol Biol       Date:  1993-03       Impact factor: 4.292

7.  Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors.

Authors:  M J Reed; L Topping; N G Coldham; A Purohit; M W Ghilchik; V H James
Journal:  J Steroid Biochem Mol Biol       Date:  1993-03       Impact factor: 4.292

8.  Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue.

Authors:  A A van Landeghem; J Poortman; M Nabuurs; J H Thijssen
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

9.  Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies.

Authors:  V H James; J M McNeill; L C Lai; C J Newton; M W Ghilchik; M J Reed
Journal:  Steroids       Date:  1987 Jul-Sep       Impact factor: 2.668

10.  Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.

Authors:  P Bolufer; E Ricart; A Lluch; C Vazquez; A Rodriguez; A Ruiz; F Llopis; J Garcia-Conde; R Romero
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

View more
  6 in total

1.  Association of obesity and circulating adipose stromal cells among breast cancer survivors.

Authors:  Sagar Ghosh; Daniel Hughes; Dorothy Long Parma; Amelie Ramirez; Rong Li
Journal:  Mol Biol Rep       Date:  2014-01-24       Impact factor: 2.316

2.  Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.

Authors:  Lyndsay V Rhodes; Melyssa R Bratton; Yun Zhu; Syreeta L Tilghman; Shannon E Muir; Virgilio A Salvo; Chandra R Tate; Steven Elliott; Kenneth P Nephew; Bridgette M Collins-Burow; Matthew E Burow
Journal:  Exp Cell Res       Date:  2011-08-30       Impact factor: 3.905

3.  Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors.

Authors:  T I Oprea; A E García
Journal:  J Comput Aided Mol Des       Date:  1996-06       Impact factor: 3.686

4.  Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Authors:  Lyndsay V Rhodes; James W Antoon; Shannon E Muir; Steven Elliott; Barbara S Beckman; Matthew E Burow
Journal:  Mol Cancer       Date:  2010-11-18       Impact factor: 27.401

5.  Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase.

Authors:  Gui-Jian Liu; Giujian Liu; Yu-Sheen Wu; David Brenin; Wei Yue; Sarah Aiyar; Anne Gompel; Ji-Ping Wang; Rajeshwar Rao Tekmal; Richard J Santen
Journal:  Breast Cancer Res Treat       Date:  2007-11-02       Impact factor: 4.872

6.  Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.

Authors:  Matthew J Ellis; William R Miller; Yu Tao; Dean B Evans; Hilary A Chaudri Ross; Yasuhiro Miki; Takashi Suzuki; Hironobu Sasano
Journal:  Breast Cancer Res Treat       Date:  2008-10-22       Impact factor: 4.872

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.